Biotransformation of fluticasone: In vitro characterization

Drug Metabolism and Disposition

Volumn 34, Issue 6, 2006, Pages 1035-1040

  Pearce, Robin E ^a,b   Leeder, J Steven ^a,b,c   Kearns, Gregory L ^a,b,c  

^a CHILDREN S MERCY HOSPITAL   (United States)

^b UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 METHYLPYRAZOLE; ALPHA NAPHTHOFLAVONE; COUMARIN; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DRUG METABOLITE; FLUTICASONE; KETOCONAZOLE; OMEPRAZOLE; QUINIDINE; SULFAPHENAZOLE;

ARTICLE; BIOTRANSFORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG INHIBITION; DRUG METABOLISM; DRUG TRANSFORMATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER MICROSOME; PRIORITY JOURNAL;

ANDROSTADIENES; ANTI-INFLAMMATORY AGENTS; BIOTRANSFORMATION; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HUMANS; KETOCONAZOLE; KINETICS; LUNG; MICROSOMES, LIVER; MIFEPRISTONE; RECOMBINANT PROTEINS;

EID: 33646757917     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.105.009043     Document Type: Article

References (20)

1. Adcock IM and Ito K (2004) Steroid resistance in asthma: a major problem requiring novel solutions or a non-issue? Curr Opin Pharmacol 4:257-262.
2. Anttila S, Hukkanen J, Hakkola J, Stjernvall T, Beaune P, Edwards RJ, Boobis AR, Pelkonen O, and Raunio H (1997) Expression and localization of CYP3A4 and CYP3A5 in human lung. Am J Respir Cell Mol Biol 16:242-249.
3. de Wildt SN, Kearns GL, Leeder JS, and van den Anker JN (1999) Cytochrome P450 3A: ontogeny and drug disposition. Clin Pharmacokinet 37:485-505.
4. Dutreix C, Peng B, Mehring G, Hayes M, Capdeville R, Pokorny R, and Seiberling M (2004) Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects. Cancer Chemother Pharmacol 54:290-294.
5. Harding SM (1990) The human pharmacology of fluticasone propionate. Respir Med 84 (Suppl A):25-29.
6. Hukkanen J, Hakkola J, Lassila A, Piipari R, Anttila S, Pelkonen O, and Raunio H (2003) Modulation of CYP3A5 by glucocorticoids and cigarette smoke in human lung-derived cells. J Pharmacol Exp Ther 304:745-752.
7. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, and Kauffman RE (2003) Developmental pharmacology - drug disposition, action and therapy in infants and children. N Engl J Med 349:1157-1167.
8. Kennedy MJ, Carpenter JM, Lozano RA, and Castile RG (2002) Impaired recovery of hypothalamic-pituitary-adrenal axis function and hypoglycemic seizures after high-dose inhaled corticosteroid therapy in a toddler. Ann Allergy Asthma Immunol 88:523-526.
9. Klees T, Sheffels P, Dale O, and Kharasch ED (2005) Metabolism of alfentanil by cytochrome P4503A (CYP3A) enzymes. Drug Metab Dispos 33:303-311.
10. Lacroix D, Sonnier M, Moncion A, Cheron G, and Cresteil T (1997) Expression of CYP3A in the human liver - evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. Eur J Biochem 247:625-634.
11. Leeder JS, Gaedigk R, Marcucci KM, Gaedigk A, Vyhlidal CA, Schindel BP, and Pearce RE (2005) Variability of CYP3A7 expression in human fetal liver. J Pharmacol Exp Ther 314:626-635.
12. Lister P, Iles R, Shaw B, and Ducharme F (2003) Inhaled steroids for neonatal chronic lung disease. Cochrane Database Syst Rev (3):CD00231.
13. Mager DE, Moledina N, and Jusko WJ (2003) Relative immunosuppressive potency of therapeutic corticosteroids measured by whole blood lymphocyte proliferation. J Pharm Sci 92:1521-1525.
14. National Asthma Education and Prevention Program (1997) Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma. National Institutes of Health Publication no. 97-4051. Bethesda, MD.
15. Newton DJ, Wang RW, and Lu AY (1995) Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 23:154-158.
16. Randell TL, Donaghue KC, Ambler GR, Cowell CT, Fitzgerald DA, and Van Asperen PP (2003) Safety of the newer inhaled corticosteroids in childhood asthma. Pediatr Drugs 5:481-504.
17. Sim SC, Edwards RJ, Boobis AR, and Ingelman-Sundberg M (2005) CYP3A7 protein expression is high in a fraction of adult human livers and partially associated with the CYP3A7*1C allele. Br J Clin Pharmacol 55:375-381.
18. Singh SD, Whale C, Houghton N, Daley-Yates P, Kirby SM, and Woodcock AA (2003) Pharmacokinetics and systemic effects of inhaled fluticasone propionate in chronic obstructive pulmonary disease. Br J Clin Pharmacol 55:375-381.
19. Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K, Hamman MA, Hall SD, and Wrighton SA (2002) Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos 30:833-891.
20. Wong J, Davies T, and O'Callaghan C (2002) Estimation of the dose of fluticasone propionate inhaled by infants after bronchiolitis: effect on urinary cortisol excretion. J Allergy Clin Immunol 110:721-727.